Artemether-Lumefantrine Dosing for Adults
For adults weighing ≥35 kg, the recommended dose of artemether-lumefantrine is 80 mg artemether plus 480 mg lumefantrine per dose, administered as 4 tablets (each containing 20 mg artemether/120 mg lumefantrine) at hours 0 and 8 on day 1, then 4 tablets twice daily on days 2 and 3, for a total of 24 tablets over 72 hours. 1
Standard Dosing Regimen
- Day 1: 4 tablets at hour 0, then 4 tablets at hour 8 1, 2
- Day 2: 4 tablets in the morning (hour 24), then 4 tablets in the evening (hour 36) 1, 2
- Day 3: 4 tablets in the morning (hour 48), then 4 tablets in the evening (hour 60) 1, 2
Total dose delivered: 480 mg artemether + 2,880 mg lumefantrine over 72 hours 1, 3
Critical Administration Requirements
Artemether-lumefantrine MUST be taken with a fatty meal or drink to achieve adequate absorption; failure to do so leads to subtherapeutic drug levels and treatment failure. 1, 2, 3 This is the most common cause of treatment failure in clinical practice. 2, 3
- The fatty meal requirement applies to every single dose 1, 3
- Minimum fat content should be approximately 6.7 g per dose 4
- Examples include milk, yogurt, or a meal containing fat 1
Weight-Based Considerations
For patients >75 kg, some guidelines suggest considering higher doses, though the standard 4-tablet regimen remains the most widely recommended 1, 3. Swiss guidelines specifically recommend extending treatment to 5 days (adding 4 additional doses) in patients with high body weight or suspected malabsorption to ensure adequate lumefantrine exposure. 3
Recent pharmacokinetic data demonstrate that standard dosing achieves adequate Day 7 lumefantrine concentrations (>200 µg/L) even in obese patients, suggesting dose modification is not routinely necessary based on weight alone. 4
Special Populations
Pregnancy: Artemether-lumefantrine is safe and recommended for use in all trimesters of pregnancy according to WHO and CDC guidelines, with cure rates of 94.9-100% and no increased risk of congenital malformations or miscarriage. 1, 2, 3
Hepatic disease: Standard dosing applies to patients with viral hepatitis or compensated liver disease, with no absolute contraindications based on hepatic status. 5 However, avoid in decompensated cirrhosis (Child-Pugh B or C) with severe malaria requiring parenteral therapy. 5
Safety Monitoring
Both artemether and lumefantrine can prolong the QTc interval; avoid in patients with baseline QTc prolongation risk or those receiving other QT-prolonging medications. 1, 2, 3 Baseline ECG screening is advised in high-risk individuals. 3
Common adverse effects include headache, vertigo, and digestive disorders, but the regimen is generally well-tolerated with superior tolerability compared to quinine-based regimens. 1
Common Pitfalls to Avoid
- Failing to ensure fatty meal co-administration is the leading cause of treatment failure 2, 3
- Confusing artemether-lumefantrine (requires fat) with dihydroartemisinin-piperaquine (requires fasting) compromises efficacy 3
- Underdosing in young children in the lowest weight bands increases recurrence risk 6
- Not directly observing the first dose to confirm proper administration with fat and monitor for immediate adverse reactions 3
Efficacy Benchmarks
The 6-dose regimen achieves cure rates of 96-100% for uncomplicated P. falciparum malaria in most settings. 2, 3, 7 Day 7 lumefantrine concentrations >280 ng/mL are strongly predictive of treatment success and reduced recurrence risk at 28 and 42 days. 6